[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

组别	例数	VEGF（ng/L）	MMP-2（mg/L）
结直肠癌组
术前	150	388.2±89.8	276.3±37.1
术后3个月	150	139.8±41.6^*	163.7±25.6^*
正常对照组	150	120.1±36.7^*	152.8±23.9^*

组别	例数	VEGF（ng/L）	MMP-2（mg/L）
结直肠癌组
术前	150	388.2±89.8	276.3±37.1
术后3个月	150	139.8±41.6^*	163.7±25.6^*
正常对照组	150	120.1±36.7^*	152.8±23.9^*

1	陈翔,吴曙辉,陆宝华,等. MMP-2、MMP-9在老年结直肠癌中的表达及与其临床病理特征的关系[J]. 实用癌症杂志,2015,30(12):1779-1781.
2	蔡瑞霞,盛霞,袁志浩,等. CD105在结直肠癌中的表达及其临床病理意义[J]. 实用癌症杂志,2005,20(5):270-272.
3	BORUP R,ROSSING M,HENAO R,et al.Molecular signatures of thyroid follicular neoplasia[J]. Endocr Relat Cancer,2010,17(3):691-708.
4	沈成龙,周国强,姚一舟,等. MMP-2、MMP-14及VEGF-C在结肠癌组织中的表达及其临床意义[J]. 现代免疫学,2016,36(1):21-26.
5	张迁,韩磊,尤文斌,等. 结直肠癌患者血清VEGF和MMP-2水平的变化及意义[J]. 承德医学院学报,2016,33(1):3-5.

RichHTML

PDF (PC)